Japan Continuous Glucose Monitoring Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 96.12 Million |
| Market Size (2029) | USD 186.25 Million |
| CAGR (2024 - 2029) | 10.99 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Japan Continuous Glucose Monitoring Devices Market Analysis
The Japan Continuous Glucose Monitoring Devices Market size is estimated at USD 96.12 million in 2024, and is expected to reach USD 186.25 million by 2029, growing at a CAGR of 10.99% during the forecast period (2024-2029).
COVID-19 disrupted all aspects of the diabetes industry worldwide and in Japan. Several companies faced disruptions in supply and distribution channels nationwide since most of the CGM device components were manufactured outside of Japan. This created a gap between the supply and demand of the devices wherein the limited inventory was available. As a result, the impact of COVID-19 was considerable concerning access to a persistent continuum of care among the Japanese diabetic population. For instance, as per the primary insights, "Almost all Japanese diabetes patients visited their hospital or clinic every 2-3 months despite the COVID-19 pandemic. However, HCPs had limited communication with their patients, which impacted the consumer base and made it difficult to gain new users. In addition, the companies dealing in diabetes care were shut down, and patients visiting hospitals/clinics were unable to provide the product's information to HCPs" (Registered Nurse, Diabetes Care Japan, Lifescan).
Diabetes is a chronic condition marked by high blood glucose levels. It is caused either by the inability to produce insulin (a hormone made by the pancreas to keep blood glucose levels in range) or by the body not being able to use insulin effectively, or both.
Type 1 diabetic patients need to take insulin throughout their lives and maintain a healthy diet and regular physical exercise. Whereas Type 2 diabetic patients need to eat healthily, be physically active, and test their blood glucose level, and may also need to take oral medication and insulin to control the glucose level in their blood. The need for monitoring blood glucose levels is on the rise among diabetic patients, mainly to avoid complications, such as cardiovascular diseases, stroke, blood disorders, blindness, and kidney disorder, among others.
Various CGM devices are available in the japan market. Dexcom develops and manufactures the current-generation G6 CGM. Terumo markets the G6 in Japan. The Dexcom G6 system features a wearable sensor attached to a user's abdomen. It automatically transmits glucose measurements every five minutes to a monitor or smart device with a dedicated application. Users can check their real-time glucose values and trends through a visualized graph. Additionally, G6 notifies users when glucose measurements fall outside a pre-set target range. It also sends alerts upon predictions of hypoglycemia occurring in 20 minutes.
Japan Continuous Glucose Monitoring Devices Market Trends
The Durables Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
A transmitter is a component of a sensor that sends the blood glucose levels to the reader, receiver, or smartphone app. Receivers are devices that receive data from transmitters and display the results on different user interfaces. The way these components of CGM devices work varies according to their manufacturers. These devices can be visible and may be required to be placed on the skin. Transmitter batteries may be rechargeable or disposable. The market segment is expected to witness growth as a result of the growing use of CGM devices among the diabetic population, growing underlying causes resulting in diabetes, market availability of these products, advantages offered by these durables, and surge in awareness regarding the use of CGM devices among the Japanese population.
Diabetes has been identified as a healthcare priority by the Japanese Ministry of Health, Labour, and Welfare. The high prevalence of type 2 diabetes is associated with a significant economic burden. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan.
Rising diabetes prevalence in Japan driving the market in the forecast year
The type 1 diabetic population in Japan is expected to increase, registering a CAGR greater than 0.4% over the forecast period.
There has been a rapid increase in the growth of diabetes in Japan. As per the IDF 2021 estimates, 11 million adults in Japan have diabetes. The objectives of diabetes management are to improve metabolic dysfunctions resulting from hyperglycemia to prevent the development or progression of diabetic complications and conditions associated with diabetes, and to enable affected individuals to maintain their quality of life and life expectancy at a level comparable to those in healthy individuals.
The Japan Diabetes Society (JDS) has set an HbA1c control target of 'less than 7.0%.' At the same time, treatment guidelines developed by the JDS recommend that the general treatment target for HbA1c should be individualized according to treatment risks and patient characteristics.
As the prevalence of diabetes increases, the condition itself and the associated complications generate a considerable and increasing economic burden on the healthcare system and society. Japan is reflecting this trend, facing a growing prevalence of T2D and T1D in the population, with an overall diabetes prevalence rate of 9.7%, as per the data published by a Kobe University study in February 2023. The potential opportunities that diabetes could generate, both in a present and future setting, are profitable for all stakeholders, ultimately creating numerous possibilities for the companies operating within the market.
Hence, the demand for continuous glucose monitoring devices and their adoption rate is also increasing. These factors are expected to drive the market studied.
Japan Continuous Glucose Monitoring Devices Industry Overview
The Japanese continuous glucose monitoring devices market is highly consolidated. Market leaders such as Dexcom, Abbott, and Medtronic are focusing on product launches and technological collaboration to increase their foothold in the market.
Japan Continuous Glucose Monitoring Devices Market Leaders
-
Dexcom
-
Medtronic
-
Abbott
-
Everesense
-
Ascensia
*Disclaimer: Major Players sorted in no particular order
Japan Continuous Glucose Monitoring Devices Market News
- October 2023: Terumo and Dexcom mutually agreed to conclude their domestic sales agency contract by the end of March 2024. Upon the termination of the distributor agreement, Terumo will no longer be responsible for the sales and support of Dexcom's CGM device in Japan. Dexcom will assume full responsibility for these operations within the country. Both Terumo and Dexcom are committed to ensuring a smooth transition and will continue to provide the same level of services and support to patients and healthcare professionals during the transition period, which will extend until the end of March 2024.
- May 2023: Dexcom showcased the accuracy, reliability, and ease of use of its Dexcom G6 CGM System and highlighted the latest clinical evidence that demonstrates the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held in Kagoshima, Japan.
Japan Continuous Glucose Monitoring DevicesMarket Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rapidly Increasing Incidence and Prevalence of Diabetes
- 4.2.2 Technological Advancements in the Market
-
4.3 Market Restraints
- 4.3.1 Monopolized Supply Chain and High Cost of Devices
-
4.4 Industry Attractiveness - Porter Five Forces
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
- 4.5 Analysis of CGM Device Distribution Channels
- 4.6 Analysis of CGM Device Prescribers
5. MARKET SEGMENTATION
-
5.1 By Component
- 5.1.1 Sensors
- 5.1.2 Durables (Receivers and Transmitters)
-
5.2 By Provinces (Quantitative Analysis)
- 5.2.1 Hokkaido
- 5.2.2 Tohoku
- 5.2.3 Kanto
- 5.2.4 Chubu
- 5.2.5 Kansai
- 5.2.6 Other Provinces
6. MARKET INDICATORS
- 6.1 Type-1 and Type -2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Abbott Diabetes Care Inc.
- 7.1.2 Dexcom Inc.
- 7.1.3 Medtronic PLC
- 7.1.4 Eversense
- 7.1.5 Ascensia
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityJapan Continuous Glucose Monitoring Devices Industry Segmentation
Continuous glucose monitoring is used to automatically keep an eye on blood sugar levels during the day and at night. At any time, one can rapidly determine their blood sugar level. They can notice trends by looking at their glucose fluctuations over several hours or days. The Japan Continuous Glucose Monitoring Devices Market is Segmented by individual components such as sensors and durables (receivers and transmitters), and by Provinces. The report offers the value (in USD) and volume (in Units) for the above segments.
| By Component | Sensors |
| Durables (Receivers and Transmitters) | |
| By Provinces (Quantitative Analysis) | Hokkaido |
| Tohoku | |
| Kanto | |
| Chubu | |
| Kansai | |
| Other Provinces |
Japan Continuous Glucose Monitoring DevicesMarket Research FAQs
How big is the Japan Continuous Glucose Monitoring Devices Market?
The Japan Continuous Glucose Monitoring Devices Market size is expected to reach USD 96.12 million in 2024 and grow at a CAGR of 10.99% to reach USD 186.25 million by 2029.
What is the current Japan Continuous Glucose Monitoring Devices Market size?
In 2024, the Japan Continuous Glucose Monitoring Devices Market size is expected to reach USD 96.12 million.
Who are the key players in Japan Continuous Glucose Monitoring Devices Market?
Dexcom, Medtronic, Abbott, Everesense and Ascensia are the major companies operating in the Japan Continuous Glucose Monitoring Devices Market.
What years does this Japan Continuous Glucose Monitoring Devices Market cover, and what was the market size in 2023?
In 2023, the Japan Continuous Glucose Monitoring Devices Market size was estimated at USD 85.56 million. The report covers the Japan Continuous Glucose Monitoring Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Japan Continuous Glucose Monitoring Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Japan Continuous Glucose Monitoring DevicesIndustry Report
Statistics for the 2024 Japan Continuous Glucose Monitoring Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Japan Continuous Glucose Monitoring Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
